A study found that PD-L1, PD-L2 and tumor mutation burden from a comprehensive genomic and transcriptomic profiling test independently predicted Keytruda (pembrolizumab) benefit in pan-solid tumors—and when combined in a multivariate signature score—predicted benefit better than PD-L1 or TMB alone.
Approximately one in 30 NIH-funded clinical trials—and more than 74,000 trial participants—were affected by grant funding disruptions caused by the Trump administration, according to an analysis in JAMA Internal Medicine.
